Literature DB >> 29523555

Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA).

Mohammad R Ostovaneh1, Bharath Ambale-Venkatesh2, Tomoki Fuji1, Hooman Bakhshi1, Ravi Shah1, Venkatesh L Murthy1, Russell P Tracy1, Eliseo Guallar1, Colin O Wu1, David A Bluemke1, João A C Lima1.   

Abstract

BACKGROUND: The association of cardiovascular diseases (CVD) with liver fibrosis is poorly understood. We aim to assess the association of liver fibrosis by T1-mapping magnetic resonance imaging and CVD in MESA (Multi-Ethnic Study of Atherosclerosis). METHODS AND
RESULTS: MESA enrolled 6814 participants free of clinical CVD at baseline (2000-2002). A subsample of participants underwent T1-mapping magnetic resonance imaging 10 years after the baseline (Y10 MESA exam, 2010-2012). Liver T1 maps were generated avoiding vessels and biliary ducts from which native T1 (n=2087) and extracellular volume fraction (ECV, n=1234) were determined. Higher ECV and native T1 were indicators of liver fibrosis. Linear regression analysis evaluated the cross-sectional relationship between liver native T1 and ECV at Y10 MESA exam with a history of CVD events (atrial fibrillation, heart failure, and coronary heart disease [CHD]). Of the 2087 participants (68.7±9.1 years; 46% females), 153 had prior CVD events (78 atrial fibrillation, 25 heart failure, and 78 CHD). History of CVD events was associated with 18.5 ms higher liver native T1 (P<0.001) and 1.4% greater ECV (P=0.06). Prior atrial fibrillation was related to higher liver native T1 (β=21.1; P=0.001) and greater ECV (β=2.2; P=0.02), whereas previous heart failure was associated with greater liver ECV (β=4.1; P=0.02). There was also a relationship of prior CHD with liver native T1 (β=13; P=0.05) and ECV (β=1.9; P=0.05), which was attenuated by adjustment for coronary artery calcium score (β=7.1 and 1.6; P=0.37 and 0.13, respectively).
CONCLUSIONS: Liver fibrosis by T1-mapping magnetic resonance imaging is associated with history of heart failure, atrial fibrillation, and CHD in a multiethnic cohort. The association of liver fibrosis and CHD is at least in part mediated by atherosclerosis.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  cardiovascular diseases; fibrosis; inflammation; liver disease; population

Mesh:

Year:  2018        PMID: 29523555      PMCID: PMC5846116          DOI: 10.1161/CIRCIMAGING.117.007241

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  52 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

Review 3.  Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.

Authors:  Daniel A Duprez
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

4.  Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.

Authors:  George B Goh; Mangesh R Pagadala; Jaividhya Dasarathy; Aynur Unalp-Arida; Ruth Sargent; Carol Hawkins; Achuthan Sourianarayanane; Amer Khiyami; Lisa Yerian; Rish Pai; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Liver Int       Date:  2014-07-05       Impact factor: 5.828

5.  Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations.

Authors:  Meng Yin; Kevin J Glaser; Jayant A Talwalkar; Jun Chen; Armando Manduca; Richard L Ehman
Journal:  Radiology       Date:  2015-07-08       Impact factor: 11.105

6.  Assessment of liver fibrosis by variable flip angle T1 mapping at 3.0T.

Authors:  Zhiming Li; Jihong Sun; Xi Hu; Ning Huang; Guocan Han; Lumin Chen; Yurong Zhou; Weixian Bai; Xiaoming Yang
Journal:  J Magn Reson Imaging       Date:  2015-08-12       Impact factor: 4.813

7.  Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI.

Authors:  Michael Haimerl; Niklas Verloh; Florian Zeman; Claudia Fellner; René Müller-Wille; Andreas G Schreyer; Christian Stroszczynski; Philipp Wiggermann
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.

Authors:  Michael Pavlides; Rajarshi Banerjee; Joanne Sellwood; Catherine J Kelly; Matthew D Robson; Jonathan C Booth; Jane Collier; Stefan Neubauer; Eleanor Barnes
Journal:  J Hepatol       Date:  2015-11-10       Impact factor: 25.083

9.  Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study.

Authors:  Michelle T Long; Xiaoyan Yin; Martin G Larson; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Laila Staerk; Darae Ko; Robert H Helm; Udo Hoffmann; Raymond T Chung; Emelia J Benjamin
Journal:  J Am Heart Assoc       Date:  2017-05-02       Impact factor: 5.501

10.  Influence of fat on liver T1 measurements using modified Look-Locker inversion recovery (MOLLI) methods at 3T.

Authors:  Ferenc E Mozes; Elizabeth M Tunnicliffe; Michael Pavlides; Matthew D Robson
Journal:  J Magn Reson Imaging       Date:  2016-01-13       Impact factor: 4.813

View more
  18 in total

1.  Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis.

Authors:  Maureen Whitsett; Jane Wilcox; Amy Yang; Lihui Zhao; Mary Rinella; Lisa B VanWagner
Journal:  Liver Int       Date:  2018-12-21       Impact factor: 5.828

2.  Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study.

Authors:  Galit Weinstein; Kendra Davis-Plourde; Jayandra J Himali; Shira Zelber-Sagi; Alexa S Beiser; Sudha Seshadri
Journal:  Liver Int       Date:  2019-06-26       Impact factor: 5.828

3.  Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke.

Authors:  Neal S Parikh; Lisa B VanWagner; Mitchell S V Elkind; Jose Gutierrez
Journal:  J Neurol Sci       Date:  2019-10-13       Impact factor: 3.181

4.  Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis.

Authors:  Michelle T Long; Emelia J Benjamin
Journal:  Circ Cardiovasc Imaging       Date:  2018-03       Impact factor: 7.792

5.  Native T1 mapping compared to ultrasound elastography for staging and monitoring liver fibrosis: an animal study of repeatability, reproducibility, and accuracy.

Authors:  Jinning Li; Huanhuan Liu; Caiyuan Zhang; Shuyan Yang; Yanshu Wang; Weibo Chen; Xin Li; Dengbin Wang
Journal:  Eur Radiol       Date:  2019-07-23       Impact factor: 5.315

Review 6.  Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents.

Authors:  Run Yang; Changming Tan; Masoud Najafi
Journal:  Inflammopharmacology       Date:  2021-11-23       Impact factor: 4.473

7.  Response to letter to the editor by Kawada on "Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke".

Authors:  Neal S Parikh; Jose Gutierrez
Journal:  J Neurol Sci       Date:  2019-11-07       Impact factor: 4.553

Review 8.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022

Review 9.  Using Zebrafish as a Disease Model to Study Fibrotic Disease.

Authors:  Xixin Wang; Daniëlle Copmans; Peter A M de Witte
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

10.  Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study.

Authors:  Xiya Lu; Zhijing Wang; Liu Yang; Changqing Yang; Meiyi Song
Journal:  Front Cardiovasc Med       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.